Search

Your search keyword '"Lotfi, Malihe"' showing total 26 results
Start Over Author "Lotfi, Malihe"
26 results on '"Lotfi, Malihe"'

4. List of contributors

Author

Agwamba, Ernest C., primary, Ahadian, Samad, additional, Ahmadi, Fatemeh Maghsood, additional, Ahmadian, Roohollah, additional, Akbari, Babak, additional, Akhtari, Negin, additional, Alarcin, Emine, additional, Alem, Halima, additional, Ancira-Cortez, Alejandra, additional, Aref, Amir Reza, additional, Avci-Adali, Meltem, additional, Ayran, Musa, additional, Azarian, Maryam, additional, Bal-Öztürk, Ayça, additional, Barabadi, Hamed, additional, Barati, Maedeh, additional, Bardouni, Mohammad Mahdi, additional, Barzegar, Sajjad, additional, Bilakaya, Besa, additional, Bozlar, Michael, additional, Bozorgchami, Negar, additional, Camlik, Gamze, additional, Cekuc, Mehmet Sertac, additional, Chakafana, Graham, additional, Chakraborty, Gulmi, additional, Chhikara, Nidhi, additional, Cruz-Nova, Pedro, additional, Davari-Kia, Kamyar, additional, De, Ranjit, additional, Degim, Ismail Tuncer, additional, Degim, Zelihagul, additional, Eivazzadeh-Keihan, Reza, additional, Ezati, Negin, additional, Farahani, Ehsan Ortegoli, additional, Farani, Marzieh Ramezani, additional, Fateh, Sahand Tehrani, additional, Fateh, Sepand Tehrani, additional, Fatehi, Dorin, additional, Ghorbani-Bidkorpeh, Fatemeh, additional, Gibbens-Bandala, Brenda, additional, Goshtasbi, Nazanin, additional, Gunduz, Oguzhan, additional, Haeri, Azadeh, additional, Hakimi, Fatemeh, additional, Hamidi, Mehrdad, additional, Hashemi, Atieh, additional, Hassan, Moustapha, additional, Hojjati, Saba, additional, Hosseinabadi, Tahereh, additional, Hosseinpour-Moghadam, Reza, additional, Huh, Yun Suk, additional, Imani, Mahsa, additional, Ipek, Tuba Canak, additional, Jabbari, Farzaneh, additional, Jahani, Reza, additional, Jounaki, Kamyar, additional, Kakavand, Melika, additional, Karami, Kimiya, additional, Karslı, Seher, additional, Katerere, David R., additional, Kaushik, Ajeet, additional, Khajeamiri, Yasaman, additional, Khan, Sofia, additional, Khoramipour, Mahsa, additional, Khoskam, Maryam, additional, Koyuncuoglu, Rumeysa, additional, Kumar, Anuj, additional, Kumar, Govindarajan V., additional, Kumar, Krishan, additional, Kumari, Sonika, additional, Lalebeigi, Farnaz, additional, Lim, Vuanghao, additional, Lotfi, Malihe, additional, Lotfi, Mohammad Javad, additional, Mahata, Manoj Kumar, additional, Makwikwi, Tendai, additional, Maleki, Ali, additional, Maleki, Aziz, additional, Maleksabet, Hanieh, additional, Manicum, Amanda-Lee E., additional, Masoumi, Niloofar, additional, Mehryab, Fatemeh, additional, Meléndez-Alafort, Laura, additional, Merati, Faezeh, additional, Mirshafiyan, Mahshad, additional, Moammeri, Ali, additional, Mohit, Elham, additional, Moradi, Ashkan, additional, Mortazavi, Seyed Alireza, additional, Mortazavi, Seyedeh Maryam, additional, Mosayebnia, Mona, additional, Mostafavi, Ebrahim, additional, Movahed, Mahsa Azami, additional, Naderi, Nooshin, additional, Naei, Vahid Yaghoubi, additional, Namazifard, Saina, additional, Nasiri, Azadeh, additional, Nasri, Negar, additional, Nazari, Hojjatollah, additional, Nejati, Omid, additional, Noqani, Hesam, additional, Ocampo-García, Blanca, additional, Ozarici, Huseyin Berkay, additional, Özcan-Bülbül, Ece, additional, Preetam, Subham, additional, Rad, Dorsa Morshedi, additional, Ramazani, Ali, additional, Rath, Rajeswari, additional, Reeves, Sheena M., additional, Rezaei, Niloufar, additional, Rostami, Sanaz, additional, Saadatidizaji, Zahra, additional, Sabzini, Mahdi, additional, Sadat, Zahra, additional, Sadighian, Somayeh, additional, Sadri, Bahareh, additional, Sahrayi, Hamidreza, additional, Saleemi, Mansab Ali, additional, Salehi-Najafabadi, Amir, additional, Samadi, Amirmasoud, additional, Sanyal, Rupa, additional, Sarrami Foroushani, Elnaz, additional, Seyedhamzeh, Mohammad, additional, Shamsabadipour, Amin, additional, Sharma, Ajay, additional, Sharma, Anil Kumar, additional, Sharma, Anirudh, additional, Sharma, Saurabh, additional, Sharma, Varruchi, additional, Singh, Jasdeep, additional, Song, Yo Han, additional, Soni, Savita, additional, Sood, Ankur, additional, Subudhi, P. Debishree, additional, Tabarzad, Maryam, additional, Tabatabaei, Mahsa Seyed, additional, Taghizadeh, Fatemeh, additional, Tayebi, Lobat, additional, Ulag, Songul, additional, Uyar, Perihan, additional, Vosough, Massoud, additional, Warkiani, Majid Ebrahimi, additional, Yavari, Maryam, additional, Yaşayan, Gökçen, additional, Yildiz, Irem, additional, Zare, Iman, additional, Zare, Mohammad Reza, additional, Zarepour, Atefeh, additional, Zarkesh, Ibrahim, additional, and Zarrabi, Ali, additional

Published
2024
Full Text
View/download PDF

12. Recent advances in CRISPR-Cas systems for colorectal cancer research and therapeutics.

Author

Khorshid Sokhangouy, Saeideh, Alizadeh, Farzaneh, Lotfi, Malihe, Sharif, Samaneh, Ashouri, Atefeh, Yoosefi, Yasamin, Bozorg Qomi, Saeed, and Abbaszadegan, Mohammad Reza

Abstract

Introduction: Colon cancer, ranked as the fourth leading global cause of cancer death, exhibits a complex progression marked by genetic variations. Over the past decade, the utilization of diverse CRISPR systems has propelled accelerated research into colorectal cancer (CRC) treatment. Areas covered: CRISPR/Cas9, a key player in this research, identifies new oncogenes, tumor suppressor genes (TSGs), and drug-resistance genes. Additionally, it facilitates the construction of experimental models, conducts genome-wide library screening, and develops new therapeutic targets, especially for targeted knockout in vivo or molecular targeted drug delivery, contributing to personalized treatments and significantly enhancing the care of colon cancer patients. In this review, we provide insights into the mechanism of the CRISPR/Cas9 system, offering a comprehensive exploration of its applications in CRC, spanning screening, modeling, gene functions, diagnosis, and gene therapy. While acknowledging its transformative potential, the article highlights the challenges and limitations of CRISPR systems. Expert opinion: The application of CRISPR/Cas9 in CRC research provides a promising avenue for personalized treatments. Its potential for identifying key genes and enabling experimental models and genome-wide screening enhances patient care. This review underscores the significance of CRISPR-Cas9 gene editing technology across basic research, diagnosis, and the treatment landscape of colon cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Non-coding RNAs as Key Regulators of the Notch Signaling Pathway in Glioblastoma: Diagnostic, Prognostic, and Therapeutic Targets

Author

Shahcheraghi, Seyed Hossein, primary, Roshani Asl, Elmira, additional, Lotfi, Malihe, additional, Ayatollahi, Jamshid, additional, Khaleghinejad, Seyed Hossein, additional, Aljabali, Alaa A., additional, Bakshi, Hamid A., additional, El-Tanani, Mohamed, additional, Charbe, Nitin, additional, Serrano-Aroca, Ángel, additional, Mishra, Vijay, additional, Mishra, Yachana, additional, Goyal, Rohit, additional, Hromić-Jahjefendić, Altijana, additional, Uversky, Vladimir N., additional, Lotfi, Marzieh, additional, and Tambuwala, Murtaza M., additional

Published
2024
Full Text
View/download PDF

16. Non-coding RNAs as Key Regulators of the Notch Signaling Pathway in Glioblastoma: Diagnostic, Prognostic, and Therapeutic Targets

Author

Shahcheraghi, Seyed Hossein, primary, Asl, Elmira Roshani, additional, Lotfi, Malihe, additional, Ayatollahi, Jamshid, additional, Khaleghinejad, Seyed Hossein, additional, Aljabali, Alaa A.A., additional, Bakshi, Hamid, additional, El-Tanani, Mohamed, additional, Said-Sadier, Najwane, additional, Almutary, Abdulmajeed G., additional, Serrano-Aroca, Ángel, additional, Mishra, Vijay, additional, Mishra, Yachana, additional, Goyal, Rohit, additional, Hromić-Jahjefendić, Altijana, additional, Uversky, Vladimir N., additional, Lotfi, Marzieh, additional, and Tambuwala, Murtaza M., additional

Published
2023
Full Text
View/download PDF

17. Application of CRISPR‐Cas9 technology in diabetes research.

Author

Lotfi, Malihe, Butler, Alexandra E., Sukhorukov, Vasily N., and Sahebkar, Amirhossein

Subjects
*TREATMENT of diabetes, *GENOME editing, *GENETIC testing, *GENOMICS, *CRISPRS, *GENETIC techniques, *MEDICAL research
Abstract

Diabetes is a chronic disorder with rapidly increasing prevalence that is a major global issue of our current era. There are two major types of diabetes. Polygenic forms of diabetes include type 1 diabetes (T1D) and type 2 diabetes (T2D) and its monogenic forms are maturity‐onset diabetes of the young (MODY) and neonatal diabetes mellitus (NDM). There are no permanent therapeutic approaches for diabetes and current therapies rely on regular administration of various drugs or insulin injection. Recently, gene editing strategies have offered new promise for treating genetic disorders. Targeted genome editing is a fast‐growing technology, recruiting programmable nucleases to specifically modify target genomic sequences. These targeted nucleases generate double‐strand breaks at target regions in the genome, which induce cellular repair pathways including non‐homologous end joining (NHEJ) and homology‐directed repair (HDR). Clustered regularly interspaced palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) is a novel gene‐editing system, permitting precise genome modification. CRISPR/Cas9 has great potential for various applications in diabetic research such as gene screening, generation of diabetic animal models and treatment. In this article, gene‐editing strategies are summarized with a focus on the CRISPR/Cas9 approach in diabetes research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Photonic nanoparticles: emerging theranostics in cancer treatment

Author

Shahcheraghi, Seyed Hossein, primary, Shahcheraghi, Seyed Hadi, additional, Lotfi, Marzieh, additional, Lotfi, Malihe, additional, Khaleghinejad, Seyed Hossein, additional, Tambuwala, Zara M, additional, Mishra, Vijay, additional, Mishra, Yachana, additional, Serrano-Aroca, Ángel, additional, A Aljabali, Alaa A, additional, El-Tanani, Mohamed, additional, Naikoo, Gowhar A, additional, Chava, Sai Raghuveer, additional, Charbe, Nitin B, additional, Bharti, Shivani, additional, Jaganathan, Saravana Kumar, additional, Goyal, Rohit, additional, Negi, Poonam, additional, Tambuwala, Murtaza M, additional, and Folorunso, Oladipo, additional

Published
2023
Full Text
View/download PDF

25. Photonic nanoparticles: emerging theranostics in cancer treatment.

Author

Shahcheraghi, Seyed Hossein, Shahcheraghi, Seyed Hadi, Lotfi, Marzieh, Lotfi, Malihe, Khaleghinejad, Seyed Hossein, Tambuwala, Zara M, Mishra, Vijay, Mishra, Yachana, Serrano-Aroca, Ángel, A Aljabali, Alaa A., El-Tanani, Mohamed, Naikoo, Gowhar A., Chava, Sai Raghuveer, Charbe, Nitin B., Bharti, Shivani, Jaganathan, Saravana Kumar, Goyal, Rohit, Negi, Poonam, Tambuwala, Murtaza M., Folorunso, Oladipo, Shahcheraghi, Seyed Hossein, Shahcheraghi, Seyed Hadi, Lotfi, Marzieh, Lotfi, Malihe, Khaleghinejad, Seyed Hossein, Tambuwala, Zara M, Mishra, Vijay, Mishra, Yachana, Serrano-Aroca, Ángel, A Aljabali, Alaa A., El-Tanani, Mohamed, Naikoo, Gowhar A., Chava, Sai Raghuveer, Charbe, Nitin B., Bharti, Shivani, Jaganathan, Saravana Kumar, Goyal, Rohit, Negi, Poonam, Tambuwala, Murtaza M., and Folorunso, Oladipo

Abstract

This review explores the potential of photonic nanoparticles for cancer theranostics. Photonic nanoparticles offer unique properties and photonics capabilities that make them promising materials for cancer treatment, particularly in the presence of near-infrared light. However, the size of the particles is crucial to their absorption of near-infrared light and therapeutic potential. The limitations and challenges associated with the clinical use of photonic nanoparticles, such as toxicity, immune system clearance, and targeted delivery to the tumor are also discussed. Researchers are investigating strategies such as surface modification, biodegradable nanoparticles, and targeting strategies to improve biocompatibility and accumulation in the tumor. Ongoing research suggests that photonic nanoparticles have potential for cancer theranostics, further investigation and development are necessary for clinical use.

26. Circular RNAs as the pivotal regulators of epithelial-mesenchymal transition in gastrointestinal tumor cells.

Author

Mahmoudian RA, Akhlaghipour I, Lotfi M, Shahidsales S, and Moghbeli M

Subjects
Humans, Epithelial-Mesenchymal Transition genetics, Phosphatidylinositol 3-Kinases, Signal Transduction genetics, RNA, Circular genetics, Gastrointestinal Neoplasms genetics, Gastrointestinal Neoplasms pathology
Abstract

Gastrointestinal (GI) cancers, as the most common human malignancies are always considered one of the most important health challenges in the world. Late diagnosis in advanced tumor stages is one of the main reasons for the high mortality rate and treatment failure in these patients. Therefore, investigating the molecular pathways involved in GI tumor progression is required to introduce the efficient markers for the early tumor diagnosis. Epithelial-mesenchymal transition (EMT) is one of the main cellular mechanisms involved in the GI tumor metastasis. Non-coding RNAs (ncRNAs) are one of the main regulatory factors in EMT process. Circular RNAs (circRNAs) are a group of covalently closed loop ncRNAs that have higher stability in body fluids compared with other ncRNAs. Considering the importance of circRNAs in regulation of EMT process, in the present review we discussed the role of circRNAs in EMT process during GI tumor invasion. It has been reported that circRNAs mainly affect the EMT process through the regulation of EMT-specific transcription factors and signaling pathways such as WNT, PI3K/AKT, TGF-β, and MAPK. This review can be an effective step in introducing a circRNA/EMT based diagnostic panel marker for the early tumor detection among GI cancer patients., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 Elsevier GmbH. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results